| Added by | mollevi |
|---|---|
| Last modified by | André Pèlegrin |
| Group name | EquipeAP |
| Item Type | Journal Article |
| Title | High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes |
| Creator | Falk et al. |
| Author | A. T. Falk |
| Author | S. Demontoy |
| Author | E. Chamorey |
| Author | M. E. Chand |
| Author | M. Gautier |
| Author | D. Azria |
| Author | S. Zaki |
| Author | D. Chevallier |
| Author | D. L. Cham Kee |
| Author | J. M. Hannoun-Levi |
| Abstract | PURPOSE: Dose escalation for prostate cancer can be achieved with a combination of external beam radiotherapy (EBRT) and brachytherapy (BT) boost to increase local control. For high-dose-rate (HDR)-BT, optimal fractionation remains under debate. The objective was to assess the clinical outcome of three schemes of HDR-BT boost. METHODS AND MATERIALS: Retrospective single institution data collection was performed. Patients received 46 Gy EBRT then an HDR-BT boost: 3 x 6 Gy, 2 x 9 Gy, or 1 x 14 Gy. HDR needles were placed under general anesthesia with endorectal ultrasonography guidance. CT-scan and treatment were performed postoperatively. RESULTS: Between 2009 and 2012, 159 patients were included. Nine patients (5.7%) were low, 32 (20.1%) intermediate, and 118 (74.2%) high risk (D'Amico classification) without significant difference between the three BT schemes. With a median followup of 61 months, 5-year biochemical relapse-free survival, 5-year local relapse-free survival, 5-year metastases-free survival, and 5-year overall survival rates were 86.6% (SE 2.7%), 98.3% (SE 1%), 95.3% (SE 1%), and 96.5% (SE 1.5%), respectively, with no significant difference between the BT schemes. The rates of acute >/= G2 genitourinary and >/=G2 gastrointestinal toxicities were 11.3% and 6.3%, respectively (p = NS). The rates of late genitourinary >/= G2 and gastrointestinal >/= G2 toxicities (at last followup) were 9.4% and 0.6% with, respectively, 0.6% and 0% of G4 (p = NS). CONCLUSIONS: Hypofractionation up to a single-fraction HDR-BT boost for prostate cancer yields similar results in terms of biochemical control and late toxicity compared with two or three-fraction schemes. Single fraction HDR-BT appears acceptable for boosting prostate cancer after definitive EBRT. |
| Publication | Brachytherapy |
| Date | Jul 25 2017 |
| Journal Abbr | Brachytherapy |
| DOI | 10.1016/j.brachy.2017.06.013 |
| ISSN | 1873-1449 (Electronic) 1538-4721 (Linking) |
| Tags | Aged, Boost, Brachytherapy, clinic, clinique hors équipe, Disease-Free Survival, Dose Fractionation, Follow-Up Studies, Gastrointestinal Diseases, High-dose-rate, Humans, Male, Male Urogenital Diseases, Middle Aged, Neoplasm Recurrence, Local, nonvisible, Prostate cancer, Prostatic Neoplasms, Retrospective Studies, Survival Rate |
| Date Added | 2018/07/20 - 10:01:50 |
| Date Modified | 2019/12/11 - 18:27:26 |
| Notes and Attachments | (Note) (Note) 28754301 (Attachment) |
Institut de Recherche en Cancérologie de
